Loading...
XETRMRK
Market cap248bUSD
, Last price  
0.00EUR
Name

Merck & Co Inc

Chart & Performance

D1W1MN
XETR:MRK chart
P/E
—
P/S
—
EPS
0.14
Div Yield, %
%
Shrs. gr., 5y
-1.01%
Rev. gr., 5y
7.29%
Revenues
60.12b
+1.40%
22,938,600,00022,011,900,00022,636,000,00024,197,700,00023,850,300,00027,428,300,00045,987,000,00048,047,000,00047,267,000,00044,033,000,00042,237,000,00039,498,000,00039,807,000,00040,122,000,00042,294,000,00046,840,000,00041,518,000,00048,704,000,00059,283,000,00060,115,000,000
Net income
365m
-97.49%
5,813,400,0004,631,300,0004,433,800,0003,275,400,0007,808,400,00012,901,300,000861,000,0006,272,000,0006,661,000,0004,404,000,00011,920,000,0004,442,000,0005,691,000,0002,568,000,0006,220,000,0009,843,000,0007,067,000,00013,049,000,00014,519,000,000365,000,000
CFO
13.01b
-31.89%
8,799,100,0007,608,500,0006,765,200,0006,999,200,0006,571,700,0003,392,000,00010,822,000,00012,383,000,00010,022,000,00011,654,000,0007,860,000,00012,421,000,00010,376,000,0006,447,000,00010,922,000,00013,440,000,00010,253,000,00014,109,000,00019,095,000,00013,006,000,000
Dividend
Apr 29, 20242.2 EUR/sh
Earnings
Feb 04, 2025

Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
URL
https://www.merck.com/
IPO date
Jan 01, 1941
Employees
67,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
60,115,000
1.40%
59,283,000
21.72%
48,704,000
17.31%
Cost of revenue
57,161,000
41,001,000
35,505,000
Unusual Expense (Income)
NOPBT
2,954,000
18,282,000
13,199,000
NOPBT Margin
4.91%
30.84%
27.10%
Operating Taxes
1,512,000
1,918,000
1,521,000
Tax Rate
51.18%
10.49%
11.52%
NOPAT
1,442,000
16,364,000
11,678,000
Net income
365,000
-97.49%
14,519,000
11.27%
13,049,000
84.65%
Dividends
(7,445,000)
(7,012,000)
(6,610,000)
Dividend yield
2.68%
2.49%
3.40%
Proceeds from repurchase of equity
(1,346,000)
2,808,000
BB yield
0.48%
-1.44%
Debt
Debt current
1,657,000
1,946,000
2,412,000
Long-term debt
35,539,000
29,758,000
31,915,000
Deferred revenue
Other long-term liabilities
7,864,000
8,323,000
9,434,000
Net debt
29,851,000
17,497,000
25,861,000
Cash flow
Cash from operating activities
13,006,000
19,095,000
14,109,000
CAPEX
(3,863,000)
(4,388,000)
(4,448,000)
Cash from investing activities
(14,083,000)
(4,960,000)
(16,555,000)
Cash from financing activities
(4,810,000)
(9,119,000)
2,593,000
FCF
(5,074,000)
14,694,000
9,675,000
Balance
Cash
7,093,000
13,192,000
8,096,000
Long term investments
252,000
1,015,000
370,000
Excess cash
4,339,250
11,242,850
6,030,800
Stockholders' equity
50,576,000
58,168,000
51,128,000
Invested Capital
77,427,750
71,843,150
73,538,200
ROIC
1.93%
22.51%
17.32%
ROCE
3.57%
21.54%
15.90%
EV
Common stock shares outstanding
2,547,000
2,542,000
2,538,000
Price
109.02
-1.74%
110.95
44.77%
76.64
-6.31%
Market cap
277,673,940
-1.55%
282,034,900
45.00%
194,512,320
-6.42%
EV
307,578,940
299,598,900
220,446,320
EBITDA
6,826,000
22,191,000
16,413,000
EV/EBITDA
45.06
13.50
13.43
Interest
1,146,000
962,000
806,000
Interest/NOPBT
38.79%
5.26%
6.11%